Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)
- 518 Downloads
Goals of work
The aim of this study was to prospectively evaluate chemotherapy-induced peripheral neuropathy (CIPN) using a patient-based instrument, the Patient Neurotoxicity Questionnaire (PNQ) and a physician-based instrument, the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) in patients with advanced or metastatic breast cancer who were treated with weekly paclitaxel.
Materials and methods
CIPN symptoms were prospectively assessed in 35 patients using the PNQ, NCI-CTC, and the Functional Assessment of Cancer Therapy (FACT)-Taxane including neurotoxicity component (Ntx) at the baseline, and 8 and 16 weeks after starting chemotherapy.
For sensory neuropathy symptoms, the reported incidence of CIPN was significantly increased during active treatment in terms of both the PNQ and NCI-CTC assessments. In contrast, there was a notable increase of patient motor neuropathy symptoms that were elucidated only by the PNQ. The PNQ grades of CIPN were widely distributed in the patient population as compared with the NCI-CTC grades for both sensory and motor neuropathy. The sensory PNQ grade was correlated with sensory NCI-CTC grade (r = 0.58) and Ntx (r = 0.51), and the motor PNQ grade was correlated with Ntx (r = 0.57).
The PNQ appears to be more sensitive and responsive than the NCI-CTC for CIPN; the PNQ appears to have diagnostic validity for evaluating CIPN in patients who are receiving neurotoxic chemotherapy.
KeywordsNeurotoxicity Peripheral neuropathy Chemotherapy Paclitaxel Breast cancer
We would like to thank all patients and physicians who participated in this study, and Miss Yumiko Nomura of J-CRSU for her assistance with data management. This study was supported by the CSPOR and Comprehensive Support Project for Health Outcomes Research (CSP-HOR) developed by the Public Health Research Foundation, Tokyo, Japan.
- 8.Fountzilas G, Dafni U, Dimopoulos MA et al (2008) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat doi: 10.1007/s10549-008-0047-9, May 16
- 26.Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642–1649 doi: 10.1200/JCO.2007.11.6699 PubMedCrossRefGoogle Scholar
- 27.Shimozuma K, Ohashi Y, Takeuchi A et al (2004) Validation of the Patient Neurotoxicity Questionnaire (PNQ) during taxane chemotherapy in a phase III randomized trial of breast cancer: N-SAS BC 02. 27th SABCS (#6037)Google Scholar
- 28.Shimozuma K, Ohashi Y, Takeuchi A et al (2006) Assessment and quantification of taxane-induced neurotoxicity in a phase III randomized trial of patients with breast cancer (AC followed by PAC/DOC vs. PAC/DOC alone): N-SAS BC 02. 42th ASCO (#8523), AltantaGoogle Scholar